Exhibit Hall Theater
Cell and gene therapies represent groundbreaking advancements in personalized medicine and regenerative therapies, employing "living" medications derived from genes, tissues, or cells to combat various diseases. Within this innovative domain, the progress in the development of cell therapies necessities in the need of high quantities and qualities of cells manufactured through precisely monitored and traceable bioprocesses.
As the industry moves more and more in the direction of allogenic cell therapies, single-use stirred-tank bioreactors have emerged as the tool of choice for the scalable production required in the transition from autologous to allogeneic cell therapies. This paradigm shift underscores a future where the scalability and control afforded by cutting-edge bioprocessing technologies are central to harnessing the full potential of cell therapies, marking a significant milestone in the journey from laboratory research to robust manufacturing frameworks.
In this talk, we will highlight the importance of process understanding and control, the implementation of automation and digital solutions significantly improve process performance.